

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the Month of December 2024**

**Commission File Number: 001-37710**

---

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

---

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

---

---

---

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release relating to HUTCHMED and Innovent jointly announce NMPA conditional approval for ELUNATE® (Fruquintinib) in combination with TYVYT® (Sintilimab Injection) for the treatment of advanced endometrial cancer

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HUTCHMED (CHINA) LIMITED

By: /s/ Johnny Cheng  
Name: Johnny Cheng  
Title: Chief Financial Officer

Date: December 3, 2024